Biotechnology company Zealand Pharma A/S (CPH:ZEAL) on Wednesday reported a negative net result of DKK26.3m for the first quarter of 2017, from January 2017 to March 2017.
This was an improvement over a negative net result of DKK77.8m in Q1 2016.
Revenues for the quarter were DKK77.6m, including milestone revenues of DKK 69.6m, as compared with DKK6.7m in Q1 2016.
According to the company, these financial results were in line with guidance and it continued to make positive progress for its product portfolio and business for the quarter.
Zealand Pharma is focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases.
(EUR1.00=DKK7.44)
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva